Advice
Following a full submission
Capecitabine (Xeloda®) is accepted for use within NHS Scotland for the adjuvant treatment of patients following surgery for Stage III (Dukes’ C stage) colon cancer. Oral capecitabine appears to be as least as effective as standard IV 5FU/FA chemotherapy with the convenience of oral administration. It should only be prescribed by oncologists.
It is more expensive than IV chemotherapy regimens. However, its use may allow changes to service delivery that have individual patient or organisational benefits.
Download detailed advice119KB (PDF)
Medicine details
- Medicine name:
- Capecitabine 150 and 500mg tablets (Xeloda®)
- SMC ID:
- 193/05
- Indication:
- Following surgery for Stage III (Dukes C stage) colon cancer
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Status
- Accepted
- Date advice published
- 08 August 2005